Medicine
Exdensur 100 mg/1 mL injection
Exdensur 100 mg/1 mL injection is a prescription medicine containing Depemokimab for subcutaneous use, marketed by GlaxoSmithKline, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to…
Key facts
- Active ingredient (INN)
- Depemokimab
- Brand
- Exdensur
- Strength
- 100 mg/1 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 1 mL
- Marketing authorisation holder
- GlaxoSmithKline
- Manufacturer
- GlaxoSmithKline
- Origin register
- US FDA, United States
- Storage
- Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Do not freeze. The prefilled syringe can be removed from the refrigerator and kept in the unopened carton, protected from light for up to 7 days at room temperature up to 86°F (30°C). Discard if left out of the refrigerator for more than 7 days. Do not shake.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- R03DX12 Depemokimab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 December 2025
- Identifiers
- RxCUI 2729271, 2729278DailyMed set ID 30332b20-2ac0-42ad-a775-d3ca7f5fe29fNDC 0173-0927Application BLA761458
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe in 1 carton / 1 mL in 1 syringe | 0173-0927-42 | GlaxoSmithKline | 16 December 2025 |
| 1 syringe in 1 carton / 1 mL in 1 syringe | 0173-0927-61 | GlaxoSmithKline | 30 March 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Depemokimab is a prescription medicine indicated for the add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older, among other approved uses. MedsAcross supplies Depemokimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DepemokimabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Exdensur prescribing information (GlaxoSmithKline) · U.S. National Library of Medicine, DailyMed
- Exdensur: European public assessment report (EPAR) · European Medicines Agency
Need Exdensur 100 mg/1 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.